Omnicell, Inc. (NASDAQ:OMCL) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analyst sentiment is “Moderate Buy”: Seven of nine covering brokerages rate Omnicell a buy, while two recommend holding; the average 12-month price target is $57.86. Some analysts have recently lowered their targets.
• Omnicell beat quarterly earnings expectations: It reported EPS of $0.58 versus the $0.42 consensus and revenue of $307.85 million versus estimates of $304.44 million. Revenue was down 0.9% year over year.
• Shares opened at $35.46, near their 52-week low of $31.75; institutional investors and hedge funds own 97.7% of the stock.

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $57.86.

Several equities analysts have recently issued reports on OMCL shares. KeyCorp reiterated an "overweight" rating on shares of Omnicell in a research report on Monday, August 24th. Zacks Research upgraded Omnicell from a "strong sell" rating to a "hold" rating in a report on Monday, September 7th. Wells Fargo & Company decreased their target price on Omnicell from $55.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Weiss Ratings raised Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 18th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd.

Hedge Funds Weigh In On Omnicell

Hedge funds have recently made changes to their positions in the business. Nykredit A S bought a new stake in Omnicell during the second quarter worth approximately $26,000. Versant Capital Management Inc grew its position in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company's stock worth $44,000 after buying an additional 294 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Omnicell by 21.9% in the third quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company's stock worth $89,000 after buying an additional 469 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in shares of Omnicell in the second quarter valued at $105,000. Finally, Central Pacific Bank Trust Division bought a new position in shares of Omnicell in the third quarter valued at $107,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $35.46 on Wednesday. Omnicell has a fifty-two week low of $31.75 and a fifty-two week high of $55.00. The firm's 50-day simple moving average is $34.64 and its 200 day simple moving average is $38.96. The company has a quick ratio of 1.45, a current ratio of 1.65 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.61 billion, a P/E ratio of 36.94, a P/E/G ratio of 1.00 and a beta of 0.88.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The firm had revenue of $307.85 million during the quarter, compared to analyst estimates of $304.44 million. During the same quarter in the prior year, the firm posted $0.51 EPS. Omnicell's revenue was down .9% compared to the same quarter last year. Equities analysts expect that Omnicell will post 1.41 EPS for the current year.

About Omnicell

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company's product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.